NPS-1034, a dual inhibitor of AXL/MET, enhances gefitinib or erlotinib sensitivity in EGFR-mutant NSCLC.268 Ningetinib, an inhibitor of c-MET, AXL and VEGFR2 showed promise when combined with gefitinib in EGFR-TKI-resistant T790M-negative NSCLC (NCT03758287). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.